Colony Group LLC Ligand Pharmaceuticals Inc Transaction History

Colony Group LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 18, 2020	SELL	$63.37 - $107.88 $734,458 - $1.25 Million	-11,590 Closed	0 $0
Q4 2019 Feb 18, 2020	SELL	$96.94 - $113.59 $151,614 - $177,654	-1,564 Reduced 11.89%	11,590 $1.21 Million
Q3 2019 Nov 26, 2019	SELL	$86.25 - $120.16 $111,435 - $155,246	-1,292 Reduced 8.94%	13,154 $1.31 Million
Q2 2019 Aug 19, 2019	BUY	$107.38 - $129.34 $1,395 - $1,681	13 Added 0.09%	14,446 $1.65 Million
Q1 2019 May 15, 2019	BUY	$105.93 - $142.47 $108,366 - $145,746	1,023 Added 7.63%	14,433 $1.81 Million
Q4 2018 Feb 15, 2019	BUY	$128.36 - $272.13 $144,276 - $305,874	1,124 Added 9.15%	13,410 $1.82 Million
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $55,751 - $72,465	-264 Reduced 2.1%	12,286 $3.37 Million
Q2 2018 Aug 15, 2018	SELL	$150.77 - $207.98 $915,475 - $1.26 Million	-6,072 Reduced 32.61%	12,550 $2.6 Million
Q1 2018 May 15, 2018	SELL	$138.63 - $182.62 $41,311 - $54,420	-298 Reduced 1.58%	18,622 $3.08 Million
Q4 2017 Feb 14, 2018	SELL	$128.36 - $147.04 $223,346 - $255,849	-1,740 Reduced 8.42%	18,920 $2.59 Million
Q3 2017 Nov 15, 2017	BUY	$120.91 - $137.94 $2.5 Million - $2.85 Million	20,660	20,660 $2.81 Million

275

18.5M

30.8K

5.2K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.04B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Colony Group LLC, based on Form 13F filings with the SEC.

Stay updated on Colony Group LLC with notifications on news.